Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
The Notice stated that, consistent with Listing Rule 5605(b)(1)(A), Nasdaq will
provide the Company a cure period in order to regain compliance as follows: (i)
until the earlier of the Company's next annual shareholders' meeting or
The Company is working diligently to find qualified individuals to add additional independent directors or otherwise adjust the composition of its board of directors as needed prior to the expiration of the applicable cure period in order to comply with Nasdaq's independent director requirements as set forth in Listing Rule 5605.
This Current Report on Form 8-K is filed to satisfy the obligation under Nasdaq Listing Rule 5810(b) and Item 3.01(a) of Form 8-K that the Company make a public announcement disclosing the deficiency no later than four business days from the date of the Notice.
© Edgar Online, source